(BEAM) Beam Therapeutics - Ratings and Ratios
Base-Editing Therapeutics, Sickle Cell, Alpha-1, Glycogen Storage, CAR-T
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 72.5% |
| Value at Risk 5%th | 105% |
| Relative Tail Risk | -12.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.29 |
| Alpha | -28.20 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.582 |
| Beta | 1.647 |
| Beta Downside | 1.957 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.20% |
| Mean DD | 44.44% |
| Median DD | 47.54% |
Description: BEAM Beam Therapeutics November 11, 2025
Beam Therapeutics Inc. (NASDAQ: BEAM) is a Cambridge-based biotech focused on precision genetic medicines that edit DNA in-vivo, targeting serious monogenic diseases in the United States.
The current pipeline centers on three liver-targeted lipid-nanoparticle (LNP) programs: BEAM-101 for sickle cell disease, BEAM-302 for severe alpha-1 antitrypsin deficiency, and BEAM-301 for glycogen storage disease type 1a. Additional early-stage assets include BEAM-103 (anti-CD117 monoclonal antibody), BEAM-104 (cell-therapy platform for sickle cell disease and β-thalassemia), and BEAM-201 plus other ex-vivo CAR-T candidates.
Beam leverages a network of research collaborations: a base-editing partnership with Pfizer covering rare liver, muscle, and CNS targets; a pre-clinical agreement with Apellis on complement-system genes; joint cardiovascular work with Verve Therapeutics; a CRISPR Cas12b licensing deal with Sana Biotechnology for cell-therapy programs; and an RNA-design collaboration with Orbital Therapeutics.
Key financial and sector metrics (as of Q2 2024): cash and cash equivalents of roughly $410 million, giving a runway into 2026 under current burn rates; R&D spend of $140 million YoY, reflecting heavy investment in early-stage programs; and a market-cap of ≈ $2.3 billion, placing Beam in the mid-range of the CRISPR-editing subsector, which analysts project to grow at a CAGR of 15-20 % through 2030 driven by expanding regulatory pathways and payer acceptance of gene-editing therapies.
If you’re looking for a deeper, data-driven assessment of Beam’s valuation and risk profile, the ValueRay platform offers a granular, model-backed analysis that can help you quantify the upside and downside scenarios.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-414.6m TTM) > 0 and > 6% of Revenue (6% = 3.34m TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA -14.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1644 % (prev 222.9%; Δ 1422 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.26 (>3.0%) and CFO -338.2m > Net Income -414.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (102.6m) change vs 12m ago 24.46% (target <= -2.0% for YES) |
| Gross Margin -639.3% (prev 7.13%; Δ -646.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.49% (prev 29.85%; Δ -25.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.47 (EBITDA TTM -430.1m / Interest Expense TTM 23.2m) >= 6 (WARN >= 3) |
Altman Z'' -8.32
| (A) 0.70 = (Total Current Assets 1.10b - Total Current Liabilities 182.6m) / Total Assets 1.31b |
| (B) -1.44 = Retained Earnings (Balance) -1.89b / Total Assets 1.31b |
| warn (B) unusual magnitude: -1.44 — check mapping/units |
| (C) -0.36 = EBIT TTM -452.2m / Avg Total Assets 1.24b |
| (D) -5.47 = Book Value of Equity -1.89b / Total Liabilities 345.1m |
| Total Rating: -8.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.95
| 1. Piotroski 0.0pt |
| 2. FCF Yield -26.49% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.16 |
| 5. Debt/Ebitda 0.27 |
| 6. ROIC - WACC (= -58.53)% |
| 7. RoE -42.86% |
| 8. Rev. Trend -25.52% |
| 9. EPS Trend -1.34% |
What is the price of BEAM shares?
Over the past week, the price has changed by +7.24%, over one month by +1.28%, over three months by +55.30% and over the past year by -10.48%.
Is BEAM a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.8 | 84.6% |
| Analysts Target Price | 46.8 | 84.6% |
| ValueRay Target Price | 21.7 | -14.2% |
BEAM Fundamental Data Overview November 25, 2025
P/S = 40.4617
P/B = 2.3326
Beta = 2.218
Revenue TTM = 55.7m USD
EBIT TTM = -452.2m USD
EBITDA TTM = -430.1m USD
Long Term Debt = 151.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 151.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.33b USD (2.25b + Debt 151.4m - CCE 1.07b)
Interest Coverage Ratio = -19.47 (Ebit TTM -452.2m / Interest Expense TTM 23.2m)
FCF Yield = -26.49% (FCF TTM -352.4m / Enterprise Value 1.33b)
FCF Margin = -632.6% (FCF TTM -352.4m / Revenue TTM 55.7m)
Net Margin = -744.4% (Net Income TTM -414.6m / Revenue TTM 55.7m)
Gross Margin = -639.3% ((Revenue TTM 55.7m - Cost of Revenue TTM 411.8m) / Revenue TTM)
Gross Margin QoQ = -1032 % (prev -1102 %)
Tobins Q-Ratio = 1.01 (Enterprise Value 1.33b / Total Assets 1.31b)
Interest Expense / Debt = 7.20% (Interest Expense 10.9m / Debt 151.4m)
Taxrate = -0.0% (0.0 / -112.7m)
NOPAT = -452.2m (EBIT -452.2m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 6.02 (Total Current Assets 1.10b / Total Current Liabilities 182.6m)
Debt / Equity = 0.16 (Debt 151.4m / totalStockholderEquity, last quarter 966.0m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -116.5m / EBITDA -430.1m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -116.5m / FCF TTM -352.4m)
Total Stockholder Equity = 967.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.63% (Net Income -414.6m / Total Assets 1.31b)
RoE = -42.86% (Net Income TTM -414.6m / Total Stockholder Equity 967.4m)
RoCE = -40.42% (EBIT -452.2m / Capital Employed (Equity 967.4m + L.T.Debt 151.4m))
RoIC = -46.75% (negative operating profit) (NOPAT -452.2m / Invested Capital 967.4m)
WACC = 11.78% (E(2.25b)/V(2.41b) * Re(12.09%) + D(151.4m)/V(2.41b) * Rd(7.20%) * (1-Tc(-0.0)))
Discount Rate = 12.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.37%
Fair Price DCF = unknown (Cash Flow -352.4m)
EPS Correlation: -1.34 | EPS CAGR: -6.04% | SUE: -0.07 | # QB: 0
Revenue Correlation: -25.52 | Revenue CAGR: -35.79% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.16 | Chg30d=-0.155 | Revisions Net=+1 | Analysts=6
EPS current Year (2025-12-31): EPS=-4.38 | Chg30d=-0.078 | Revisions Net=-6 | Growth EPS=+4.3% | Growth Revenue=-37.6%
EPS next Year (2026-12-31): EPS=-4.56 | Chg30d=-0.260 | Revisions Net=-8 | Growth EPS=-3.9% | Growth Revenue=+12.5%
Additional Sources for BEAM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle